How An Ancient Medicine Is Taking On The $16 Trillion Pharmaceutical Industry

FN Media Group Presents Market Commentary


London – December 3, 2020 – 2021 could be a big year for this soon-to-be $16-trillion biotech opportunity. More importantly, it could be a big year for companies pioneering a new form of therapy that could effectively treat the world’s #1 disability. It’s a disability that’s costing the economy $1 trillion in lost production every single year. In fact, the revolutionary treatment could be at our doorstep by 2021. And the next few months are critical.   Mentioned in today’s commentary includes:  Constellation Brands, Inc. (NYSE: STZ), Molson Coors Beverage Company (NYSE: TAP), Altria Group, Inc. (NYSE: MO), GW Pharmaceuticals plc (NASDAQ: GWPH), Curaleaf Holdings, Inc. (OTCQX: CURLF).


Why? Soon, global spending on mental healthcare will hit $16 trillion, and researchers say it has huge implications for people with…


  • Depression and anxiety
  • PTSD
  • Addiction
  • And many other disabling diseases…


And one company, Lobe Sciences (LOBE; GTSIF), is on the cutting edge of this new ‘transformational medicine.”


Breakthrough Therapy Backed By Science


Working in partnership with the University of Miami, Lobe Sciences is on the leading edge of this biotech breakthrough.


Lobe points to a Johns Hopkins study of the efficacy of these compounds for treatment of depression and anxiety (a market to grow to $18.9 billion by 2026) that concluded that psilocybin eased depression and anxiety in patients with life-threatening cancer.


But that was back in 2016. Since, a collection of new studies has taken this far beyond cancer patients and into the general population suffering from widespread depression, anxiety and PTSD. According to Alan Davis, the author of one such 2020 study and a faculty member at Johns Hopkins University and Ohio State University, psilocybin’s effect was “more than four times greater”.


Smart Money Is Going All In


Tim Ferriss, angel investor extraordinaire funded Johns Hopkins’ psychedelic research center with over $2 million. Ferriss says this is the world’s proof-of-concept demonstration–the Silicon Valley of psychedelics.


Brad Loncar, lead biotech investor at Loncar Investments, pinpointed the “ultimate sign for investors” when big pharma got its first approval for a psychedelic-based anti-depressant in the Spring of 2019.


Multi-billionaire and PayPal co-founder Peter Thiel has put big money into this industry. Mike Novogratz has also been selling the psychedelic space for years, lauding its massive investment merits.


Johnson & Johnson has been pouring money into R&D for years. When the FDA approved SPRAVATO ketamine-like nasal spray as an antidepressant in 2019, it was a signal to investors that a new side of biotech was about to explode.


And Lobe is close to a transformational PTSD development, too.  Among four others, it boasts a patent pending for a nasal mist transducer device that aims to offer a completely transformational approach to PTSD treatment. Development is already under way and the next news to come out may not just be transformational for PTSD—but for the company, as well.


The Multi-Billion Mental Health Market


As of 2020, more than 264 million people of all ages suffer from depression, according to the World Health Organization. Additionally, 1 in 13 people will develop PTSD at some point in their life. During the global pandemic… 1 in 20 women… and 1 in 50 men were newly diagnosed. Depression is now the No. 1 cause of disability in the world.


Considering many other mental disorders that psychedelic researchers are working to address, this could be a massive market opportunity. The functional mushroom market is expected to be worth more than $34 billion by 2024, according to data from Modor Intelligence. And Lobe Sciences (LOBE; GTSIF) is working hard to carve out its own piece of this market. Lobe already has five provisional patent applications on its therapy and methods… and the company’s future looks bright.


The ‘Brain Science’ Boom


Just over the past year, Denver, Oakland, Santa Cruz, Ann Arbor, Oregon and Washington DC decriminalized psilocybin. The therapeutic potential of psychedelic drugs to treat the profound distress of Western society is becoming undeniable. Even the FDA thinks so.


Similar research has been shown to be 80% effective… compared to 20%-30% for big pharma treatments. More studies will be published soon… building on this base of research.


Surrounded by a patent moat and armed with revolutionary tech, Lobe Sciences (LOBE; GTSIF) is perfectly positioned to take advantage of the 2021’s transformational science trend.


The Same Pattern Has Already Occurred In The Cannabis Boom


Constellation Brands (STZ), a beverage conglomerate with a stake in everything from Corona to Modelo, shook up the pot world in 2017 when it invested $191 million for a 9.9% stake in Canopy Growth, and followed it up a year later sinking an additional $4 billion into Canopy Growth Corp.


And earlier this year, Constellation raised its stake in the promising cannabis giant once again, investing another $174 million into Canopy, raising its stake to 55.8%. David Klein, CEO of Canopy Growth, noted “This additional investment validates the work our team has done since attracting the initial investment in 2017. It also strengthens our ability to pursue the immense market and product opportunities available to Canopy in Canada, the US and other key global markets.”


Molson Coors (TAP) is another iconic multi-national beer company, with brands that are recognizable across the United States and Canada. Not to be left behind in the marijuana boom, Molson Coors is also developing a line of non-alcoholic cannabis-based beverages with its partner, the HEXO Corporation.


In August of this year, Molson Coors finally unveiled its cannabis drinks in its joint venture with HEXO. The lineup includes five new beverages containing CBD and THC. CEO Scott Cooper, CEO of Truss Beverage, the product of the joint venture, noted, “We’re thrilled to be introducing Canadians to new beverage options and leading the cannabis beverage category with our variety of products.”


Big Tobacco is all in on this market, as well. Altria (MO) got into the marijuana game in a big way in 2018, investing $1.8 billion in the Canadian pot firm Cronos Group. The deal sent Cronos stock into the stratosphere and positioned Altria as one of the first mainstream tobacco firms to take a hard line in support of the cannabis market.


Year-to-date, Altria has seen its share price fall by 18%. But that doesn’t mean it’s not still a good buy. As the cannabis industry continues to gain traction, Altria offers potential shareholders something many other stocks in the industry don’t: dividends. Altria has maintained its high-dividend yield for years now, and though its share price has slipped slightly this year, its dividend payouts are still appealing.


GW Pharmaceuticals (GWPH) got into the cannabis game through a major industry milestone. Back in 2018, GW Pharma received approval for its cannabis-based drug Epidiolex from the Federal Drug Administration. It was the first FDA approved drug based on cannabis for the American market…and GW Pharma’s stock enjoyed a huge boost at the news.


GW had a stellar third-quarter, reporting a yearly growth in revenue of 50% due in part to the sales of Epidiolex. Justin Gover, GW’s CEO explained, “We are pleased to report strong revenue growth in the 3rd quarter despite the challenges presented by COVID-19. Epidiolex meets a serious unmet need within the field of epilepsy and we expect the product to demonstrate continued strong growth in the months and years ahead,” adding, “The recent expanded indication for the treatment of seizures associated with TSC has been very well received by patients, clinicians and payers.”


Curaleaf Holdings (CURLF) is an up-and-coming U.S. cannabis company with big plans for vertical integration. The multi-faceted company has its hands in all levels of the cannabis game, where it cultivates and manufactures a wide range of products, operates dispensaries, and much more.


The Massachusetts-based company has seen significant growth since it went public in what the Motley Fool called “the largest cannabis debut in history.” And it’s lived up to the hype. Curaleaf has had a stellar year, with its stock price bouncing from a low of $3.16 back in March to an all-time high of $10.88 at the time of writing.




PAID ADVERTISEMENT. This article is a paid advertisement. and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Lobe Sciences to conduct investor awareness advertising and marketing. Lobe paid the Publisher to produce and disseminate five similar articles and additional banner ads at a rate of sixty thousand US dollars per article. This compensation should be viewed as a major conflict with our ability to be unbiased.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by Lobe) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.


SHARE OWNERSHIP. The Publisher owns shares and/or stock options of the featured companies and therefore has an additional incentive to see the featured companies’ stock perform well. The Publisher does not undertake any obligation to notify the market when it decides to buy or sell shares of the issuer in the market. The Publisher will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.


FORWARD LOOKING STATEMENTS. This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Factors that could cause actual results to differ include, but are not limited to, changing governmental laws and policies impacting the company’s business including the legality of Psilocybin and other psychedelics, the ability of the company to exercise or sell its option to acquire shares of Cowlitz County Cannabis Cultivation or otherwise monetize its interest in Cowlitz, the degree of success with research and development of the company’s medicines and devices, the success of clinical trials, governmental approval or clearance of the company’s medicines and devices, the size and growth of the market for the companies’ products and services, the ability of management to execute its business plan, the continuity of management, the companies’ ability to fund its capital requirements in the near term and long term, pricing pressures, etc.


INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.


TERMS OF USE. By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


INTELLECTUAL PROPERTY. is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders.  The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.


DISCLAIMER: is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with or any company mentioned herein.  The commentary, views and opinions expressed in this release by are solely those of and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.  FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.


This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.


Contact Information:

Media Contact e-mail:  U.S. Phone: +1(954)345-0611